SVB Leerink Maintains Market Perform on TCR2 Therapeutics, Lowers Price Target to $3
SVB Leerink analyst Jonathan Chang maintains TCR2 Therapeutics (NASDAQ:TCRR) with a Market Perform and lowers the price target from $7 to $3.
42 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Forge Global Holdings Inc. (NYSE: FRGE) shares jumped 67.7% to $16.95. True Global Ventures’ portfolio company Forge Global Holdings completed its business combination with Motive Capital Corp on the 22nd of March, 2022.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 505 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 147 companies achieved new lows for the year.
Goldman Sachs Downgrades TCR2 Therapeutics to Neutral, Lowers Price Target to $5
Goldman Sachs downgrades TCR2 Therapeutics (NASDAQ:TCRR) from Buy to Neutral and lowers the price target from $28 to $5.
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.
HC Wainwright & Co. Maintains Buy on TCR2 Therapeutics, Lowers Price Target to $19
HC Wainwright & Co. analyst Robert Burns maintains TCR2 Therapeutics (NASDAQ:TCRR) with a Buy and lowers the price target from $25 to $19.